# A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19

> **NCT04515147** · PHASE2 · COMPLETED · sponsor: **CureVac** · enrollment: 668 (actual)

## Conditions studied

- Coronavirus
- Covid19
- SARS-CoV-2
- Severe Acute Respiratory Syndrome

## Interventions

- **BIOLOGICAL:** CVnCoV 6 μg
- **BIOLOGICAL:** CVnCoV 12 μg
- **BIOLOGICAL:** Hepatitis A vaccine
- **BIOLOGICAL:** Pneumococcal vaccine
- **BIOLOGICAL:** CVnCoV 12μg

## Key facts

- **NCT ID:** NCT04515147
- **Lead sponsor:** CureVac
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-21
- **Primary completion:** 2022-02-21
- **Final completion:** 2022-02-21
- **Target enrollment:** 668 (ACTUAL)
- **Last updated:** 2023-09-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04515147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04515147, "A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04515147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*